J Clin Neurol.
2020 Jul;16(3):355-368. 10.3988/jcn.2020.16.3.355.
Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
- Affiliations
-
- 1Department of Neurology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea
- KMID: 2506597
- DOI: http://doi.org/10.3988/jcn.2020.16.3.355
Abstract
- Considerable progress has been made in treatments for multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) over the last several decades. However, the present treatments do not show satisfactory efficacy or safety in a considerable proportion of patients, who experience relapse or disability progression despite receiving treatment and suffer from side effects, which can be severe. Improvements in the understanding of the pathophysiologies of MS and NMOSD have led to numerous therapeutic approaches being proposed and developed. Monoclonal antibodies (mAbs) are receiving increasing attention because of their specificity of action and likelihood of high efficacy with fewer side effects. Many mAbs have been evaluated, and some have been approved for MS or NMOSD treatment. This article reviews the use of mAbs for treating MS and NMOSD, including summarizing their mechanisms of action, efficacy, and safety profiles.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Differential Diagnosis between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
- Postpartum Relapse of Neuromyelitis Optica Spectrum Disorder after a Long Period of Spontaneous Remission
- Narcolepsy Followed by Intractable Vomiting Caused by Recurrent Brain Involvement in Neuromyelitis Optica Spectrum Disorder
- Autonomic dysfunction in multiple sclerosis and neuromyelitis optica spectrum disorder
- Clinical and Radiological Features of Myelin Oligodendrocyte Glycoprotein-Associated Myelitis in Adults
